Form 4: Vanda Pharmaceuticals SVP, CFO & Treasurer Kevin Patrick Moran Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to RSU settlement.
Summary
- On March 1, 2025, Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reported a transaction.
- 26,941 shares of common stock were disposed of to satisfy tax withholding obligations related to the settlement of vested RSUs at a price of $4.76.
- Following the transaction, Moran directly owns 328,822 shares of Vanda Pharmaceuticals' common stock.
- Moran also indirectly owns 635 shares through his spouse.
Sentiment
Score: 5
Explanation: This Form 4 filing is a routine disclosure of stock transactions related to tax obligations. It doesn't indicate a positive or negative sentiment towards the company's prospects.
Industry Context
This is a routine filing related to executive compensation and tax obligations. It doesn't necessarily reflect a change in the executive's long-term outlook on the company.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of transaction: shares withheld for tax obligations related to RSU settlement. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.